Inactive Instrument

IGI Laboratories, Inc. Share Price Nyse

US4495751095

End-of-day quote Nyse Other stock markets
- ^USD	-

2022	Teligent, Inc. Went Out of Business	CI
2022	Second Amended Liquidation Plan Approved for Teligent, Inc.	CI

on all our subscriptions*

Last Days!

Take advantage of the offer

* See conditions on site

Latest news about IGI Laboratories, Inc.

Teligent, Inc. Went Out of Business	26/22/26	CI
Second Amended Liquidation Plan Approved for Teligent, Inc.	15/22/15	CI
Second Motion for Exclusivity Period Extension Approved For Teligent, Inc.	25/22/25	CI
Second Amended Joint Liquidation Plan Filed by Teligent, Inc.	24/22/24	CI
First Amended Disclosure Statement Approved for Teligent, Inc.	29/22/29	CI
First Amended Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	27/22/27	CI
Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	08/22/08	CI
First Motion for Exclusivity Period Extension Approved For Teligent, Inc.	01/22/01	CI
Motion for Case Conversion Filed by Teligent, Inc.	23/22/23	CI
First Motion for Exclusivity Period Extension Filed by Teligent, Inc.	10/22/10	CI
Hikma Pharmaceuticals Closes $46 Million Purchase of Teligent's Canadian Assets	03/22/03	MT
Pharmaceutical Associates, Inc. completed the acquisition of Generic and Branded US Marketing Authorizations of Teligent, Inc. (OTCPK:TLGT.Q).	03/22/03	CI
Hikma Pharmaceuticals PLC completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q).	03/22/03	CI
Motion for Asset Sale Approved for Teligent, Inc.	19/22/19	CI
Motion for Asset Sale Approved for Teligent, Inc.	19/22/19	CI

More news

Press releases IGI Laboratories, Inc.

Hikma's diversified business delivers resilient H1 performance	05/22/05	AQ
Hikma expands into Canada with acquisition of Teligent sterile injectable assets	18/22/18	AQ
What We're Reading This Week [November 15, 2021]	17/21/17	AQ
Teligent : Company is arranging $12 million debtor-in-possession financing from its senior secured lenders and access to its cash collateral on a consensual basis - Form 8-K	16/21/16	PU
TELIGENT, INC. : Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers, Regulation (form 8-K)	16/21/16	AQ

More press releases

News in other languages on IGI Laboratories, Inc.

ENQUETE CREDIT : Les gérants se montrent plus optimistes	01/18/01
ENQUETE CREDIT : Les gérants abordent la rentrée avec prudence	03/18/03
ENQUETE CREDIT : Les gérants restent sur leurs gardes	02/18/02
BONDS : Le marché primaire du crédit en euro redémarre en trombe	16/17/16
Les émetteurs français et allemands dynamisent le marché du crédit	28/17/28

More news

Managers and Directors - IGI Laboratories, Inc.

Managers	Title	Age	Since
Alyssa Lozynski DFI	Director of Finance/CFO	34	23/21/23
Vladimir Kasparov PRN	Corporate Officer/Principal	-	14/21/14
Joseph Benesch AUD	Comptroller/Controller/Auditor	57	01/21/01

Members of the board	Title	Age	Since
Thomas Sabatino BRD	Director/Board Member	65	01/17/01
Bradley Eric Scher BRD	Director/Board Member	63	14/21/14
Carole Ben-Maimon BRD	Director/Board Member	65	29/16/29

More insiders

Teligent, Inc. is a generic pharmaceutical company. The Company is focused on the development, manufacturing and marketing of a portfolio of generic pharmaceutical products under its own label and private label for other pharmaceutical companies in topical, injectable, complex and other dosage forms. It also provides contract development and manufacturing services to the prescription and over-the-counter (OTC) pharmaceutical and cosmetic markets. Under the Company's own label, it markets and sells generic topical, and generic and branded generic injectable pharmaceutical products in the United States. In the United States, the Company markets approximately 37 generic topical pharmaceutical products and one branded injectable pharmaceutical product. The Company's portfolio of hospital-based sterile injectable products, including cephalosporins, Cefotan (Cefotetan for Injection), Fortaz (Ceftazidime) and Zinacef (Cefuroxime Sodium).

Sector

More about the company